Ardelyx Surges as Analysts Boost Targets on Strong Ibsrela Outlook
Ardelyx shares jumped after strong Ibsrela guidance, multiple analyst upgrades, higher price targets, and a faster path to $1B in revenue.
/ 907 items
#Healthcare↓
Tilray Brands Reports Narrower Q2 Loss Despite Mixed Sales Performance
Tilray (TLRY) narrows Q2 losses to $43.5M with 3% revenue growth driven by cannabis gains, though beverage sales decline 21% amid international expansion strategy.
Merck Eyes $28-32 Billion Deal for Cancer Drugmaker Revolution Medicines
Merck negotiates potential acquisition of Revolution Medicines for up to $32B, seeking new cancer treatments as Keytruda patent expiration looms in 2028.
Acrivon Cancer Drugs: Small Trials, Big Risks & Cash Concerns
Acrivon Therapeutics (ACRV) announces clinical trial data for experimental cancer drugs ACR-368 and ACR-2316, but significant challenges remain with limited cash runway and unproven efficacy.
Raymond James Starts Coverage on Evommune with Strong Buy Rating
Raymond James begins coverage of Evommune with a Strong Buy rating and a $40 price target, highlighting key Phase 2 clinical catalysts expected in 2026.
ELVN-001 Shows 69% Response Rate in CML Phase 1b Trial Results
Enliven Therapeutics (ELVN) reports encouraging Phase 1b results for ELVN-001, a new treatment for chronic myeloid leukemia, with strong response rates and excellent safety profile.